# Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

> **NCT00924352** · PHASE1,PHASE2 · COMPLETED · sponsor: **Accelerated Community Oncology Research Network** · enrollment: 56 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Ixabepilone

## Key facts

- **NCT ID:** NCT00924352
- **Lead sponsor:** Accelerated Community Oncology Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00924352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00924352, "Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00924352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*